The Use of Lentinan for Treating Gastric Cancer
Natural compounds containing fungal β-glucans have been used to improve general health for thousands of years in China and Japan. Lentinan, the backbone of β-(1, 3)-glucan with β-(1, 6) branches, is one of the active ingredients purified from Shiitake mushrooms and has been approved as a biological...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Bentham Science Publishers
2013
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664515/ |
| id |
pubmed-3664515 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-36645152013-06-04 The Use of Lentinan for Treating Gastric Cancer Ina, Kenji Kataoka, Takae Ando, Takafumi Article Natural compounds containing fungal β-glucans have been used to improve general health for thousands of years in China and Japan. Lentinan, the backbone of β-(1, 3)-glucan with β-(1, 6) branches, is one of the active ingredients purified from Shiitake mushrooms and has been approved as a biological response modifier for the treatment of gastric cancer in Japan. Despite recent advances in chemotherapeutic agents, unresectable or recurrent gastric cancer remains an incurable disease, with survival rates being far from satisfactory. Recent clinical studies have shown that chemo-immunotherapy using lentinan prolongs the survival of patients with advanced gastric cancer, as compared to chemotherapy alone. In addition, trastuzumab, an antibody against HER2/neu growth factor receptor, has been used for the treatment of gastric cancer in combination with cytotoxic chemotherapeutic agents. Lentinan may exert a synergistic action with anti-cancer monoclonal antibodies to activate complement systems through the mechanism of antibody-dependent cellular cytotoxicity and complement dependent cytotoxicity. Because a better understanding of its biological activities should enable us to use lentinan more efficiently in the treatment of gastric cancer, immunological effects provided by β-glucans, a possible mode of action of lentinan, and its clinical application including future potential uses are discussed in the present review. Bentham Science Publishers 2013-06 2013-06 /pmc/articles/PMC3664515/ /pubmed/23092289 http://dx.doi.org/10.2174/1871520611313050002 Text en © 2013 Bentham Science Publishers http://creativecommons.org/licenses/by/2.5/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Ina, Kenji Kataoka, Takae Ando, Takafumi |
| spellingShingle |
Ina, Kenji Kataoka, Takae Ando, Takafumi The Use of Lentinan for Treating Gastric Cancer |
| author_facet |
Ina, Kenji Kataoka, Takae Ando, Takafumi |
| author_sort |
Ina, Kenji |
| title |
The Use of Lentinan for Treating Gastric Cancer |
| title_short |
The Use of Lentinan for Treating Gastric Cancer |
| title_full |
The Use of Lentinan for Treating Gastric Cancer |
| title_fullStr |
The Use of Lentinan for Treating Gastric Cancer |
| title_full_unstemmed |
The Use of Lentinan for Treating Gastric Cancer |
| title_sort |
use of lentinan for treating gastric cancer |
| description |
Natural compounds containing fungal β-glucans have been used to improve general health for thousands of years in China and Japan. Lentinan, the backbone of β-(1, 3)-glucan with β-(1, 6) branches, is one of the active ingredients purified from Shiitake mushrooms and has been approved as a biological response modifier for the treatment of gastric cancer in Japan. Despite recent advances in chemotherapeutic agents, unresectable or recurrent gastric cancer remains an incurable disease, with survival rates being far from satisfactory. Recent clinical studies have shown that chemo-immunotherapy using lentinan prolongs the survival of patients with advanced gastric cancer, as compared to chemotherapy alone. In addition, trastuzumab, an antibody against HER2/neu growth factor receptor, has been used for the treatment of gastric cancer in combination with cytotoxic chemotherapeutic agents. Lentinan may exert a synergistic action with anti-cancer monoclonal antibodies to activate complement systems through the mechanism of antibody-dependent cellular cytotoxicity and complement dependent cytotoxicity. Because a better understanding of its biological activities should enable us to use lentinan more efficiently in the treatment of gastric cancer, immunological effects provided by β-glucans, a possible mode of action of lentinan, and its clinical application including future potential uses are discussed in the present review. |
| publisher |
Bentham Science Publishers |
| publishDate |
2013 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3664515/ |
| _version_ |
1611981220597465088 |